Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Amended claims 1, 2, 5, 6, 8, 12, 15, 17, 18, 19-26 and new claims 30-32 are pending.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Previously presented rejection of claim(s) 1, 2, 5, 6, 8, 12, 22-25, 26,
15, 17, 18, 19, 20, 21, 22, 23, 24, 25 and 26 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Albrecht WO 2016112298 equivalent to US10239861 is maintained for reasons of record.
Amendments to claims excluding certain specific compounds are noted.
Response:
Applicants arguments are not persuasive.
At the top of page 3 of previous action is Albrecht compound that falls under the scope of the compounds of claimed formulae
(and correlated with R groups in the previous action), and
pictured at top of dependent claim 25 numbered page 8 (second structure)
and
consistent with (see Applicants Remarks 03/12/2026 last paragraph numbered page 11)
PNG
media_image1.png
82
662
media_image1.png
Greyscale
Previously presented rejection of claims 15, 17, 18- 21, 25 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Humphreys, Journal of Medicinal Chemistry (2017), 60(2), 695-709.
As pointed out earlier, Humphreys not only taught compounds wherein R7 heterocycle directly attached to NH, but also R7 aryl directly attached to NH, substituted or unsubstituted, unfused and fused compounds that fall under the scope of the instant formulae. For example, instant dependent claim 25 numbered page 8, 13th compound as pictured is at page 700 Scheme 2 of Humphreys, which makes Remark at page 12
PNG
media_image2.png
50
616
media_image2.png
Greyscale
questionable.
As to the
PNG
media_image3.png
30
140
media_image3.png
Greyscale
Applicant correctly points out that Examiner does not provide screen shot or catalog.
Examiner notes that search for compounds in patent office provided data bases do indicate that many compounds falling under the scope of the claimed formulae are available for purchase (and also as Library compounds in NIH data bases). Getting documents such as catalogs to support whether these compounds are to satisfy the
PNG
media_image3.png
30
140
media_image3.png
Greyscale
is difficult. The difficulty is not getting the catalog from the seller, but the available catalogs are updated ones with publication dates that are often after the priority date. That said, in this case, the compounds cited for rejections as pointed out are in the references.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Previously presented rejection of claim(s) 1, 2, 5, 6, 8, 12, 15, 17, 18, 19-26 and new claims 30-32 are rejected under 35 U.S.C. 103 as being unpatentable over Albrecht WO 2016112298 and Humphreys, Journal of Medicinal Chemistry (2017), 60(2), 695-709.is maintained for reasons of record.
Note with respect to the compound of claim 30: This is obvious analog of cited compounds. It is an analog of the Humphreys compound of 25 pointed out in this action, with same invariable core structure with the aminoethyl chain decorating the core. MPEP 2144.09 Close Structural Similarity Between Chemical Compounds (Homologs, Analogues, Isomers) [R-01.2024] speaks to the issue here.
Applicants are argument are considered but are not persuasive.
Applicants arguments focus on the following:
The biological property of the compounds (and potential intended use) of the claimed compounds are different.
Response:
The claims being examined are compound (product) claims. A compound and its property are inseparable.
As per MPEP 2112 Requirements of Rejection Based on Inherency; Burden of Proof [R-10.2019], "[T]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art’s functioning, does not render the old composition patentably new to the discoverer."
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIZAL S CHANDRAKUMAR whose telephone number is (571)272-6202. The examiner can normally be reached M-F 8-5 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/NIZAL S CHANDRAKUMAR/Primary Examiner, Art Unit 1625